Sarcoidosis
4
Pipeline Programs
4
Companies
4
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
On Market (1)
Approved therapies currently available
GS
Competitive Landscape
4 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Gilead SciencesAmbrisentan
United TherapeuticsInhaled Treprostinil
AbbottAdalimumab
Cook MedicalEndosonography
Clinical Trials (4)
Total enrollment: 32 patients across 4 trials
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Start: Nov 2008Est. completion: Nov 201116 patients
Phase 2/3Completed
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
Start: Jan 2020Est. completion: Dec 20255 patients
Phase 2Completed
Trial of Adalimumab in Progressive Sarcoidosis
Start: Apr 2006Est. completion: Sep 200811 patients
Phase 2Terminated
EBUS vs EUS-B for Diagnosing Sarcoidosis
Start: May 2015Est. completion: Jun 2018
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space